1
|
Glatfelter GC, Vandeputte MM, Chen L, Walther D, Tsai MHM, Shi L, Stove CP, Baumann MH. Alkoxy chain length governs the potency of 2-benzylbenzimidazole 'nitazene' opioids associated with human overdose. Psychopharmacology (Berl) 2023; 240:2573-2584. [PMID: 37658878 DOI: 10.1007/s00213-023-06451-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 08/15/2023] [Indexed: 09/05/2023]
Abstract
RATIONALE Novel synthetic opioids (NSOs) are emerging in recreational drug markets worldwide. In particular, 2-benzylbenzimidazole 'nitazene' compounds are problematic NSOs associated with serious clinical consequences, including fatal respiratory depression. Evidence from in vitro studies shows that alkoxy chain length can influence the potency of nitazenes at the mu-opioid receptor (MOR). However, structure-activity relationships (SARs) of nitazenes for inducing opioid-like effects in animal models are not well understood compared to relevant opioids contributing to the ongoing opioid crisis (e.g., fentanyl). OBJECTIVES Here, we examined the in vitro and in vivo effects of nitazene analogues with varying alkoxy chain lengths (i.e., metonitazene, etonitazene, isotonitazene, protonitazene, and butonitazene) as compared to reference opioids (i.e., morphine and fentanyl). METHODS AND RESULTS Nitazene analogues displayed nanomolar affinities for MOR in rat brain membranes and picomolar potencies to activate MOR in transfected cells. All compounds induced opioid-like effects on locomotor activity, hot plate latency, and body temperature in male mice, and alkoxy chain length markedly influenced potency. Etonitazene, with an ethoxy chain, was the most potent analogue in MOR functional assays (EC50 = 30 pM, Emax = 103%) and across all in vivo endpoints (ED50 = 3-12 μg/kg). In vivo SARs revealed that ethoxy, isopropoxy, and propoxy chains engendered higher potencies than fentanyl, whereas methoxy and butoxy analogues were less potent. MOR functional potencies, but not MOR affinities, were positively correlated with in vivo potencies to induce opioid effects. CONCLUSIONS Overall, our data show that certain nitazene NSOs are more potent than fentanyl as MOR agonists in mice, highlighting concerns regarding the high potential for overdose in humans who are exposed to these compounds.
Collapse
Affiliation(s)
- Grant C Glatfelter
- Designer Drug Research Unit, National Institute On Drug Abuse, Intramural Research Program, Baltimore, MD, USA.
| | - Marthe M Vandeputte
- Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - Li Chen
- Computational Chemistry and Molecular Biophysics Section, National Institute On Drug Abuse, Intramural Research Program, Baltimore, MD, USA
| | - Donna Walther
- Designer Drug Research Unit, National Institute On Drug Abuse, Intramural Research Program, Baltimore, MD, USA
| | - Meng-Hua M Tsai
- Computational Chemistry and Molecular Biophysics Section, National Institute On Drug Abuse, Intramural Research Program, Baltimore, MD, USA
| | - Lei Shi
- Computational Chemistry and Molecular Biophysics Section, National Institute On Drug Abuse, Intramural Research Program, Baltimore, MD, USA
| | - Christophe P Stove
- Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - Michael H Baumann
- Designer Drug Research Unit, National Institute On Drug Abuse, Intramural Research Program, Baltimore, MD, USA
| |
Collapse
|
2
|
Wicks C, Hudlicky T, Rinner U. Morphine alkaloids: History, biology, and synthesis. THE ALKALOIDS. CHEMISTRY AND BIOLOGY 2021; 86:145-342. [PMID: 34565506 DOI: 10.1016/bs.alkal.2021.04.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
This chapter provides a short overview of the history of morphine since it's isolation by Sertürner in 1805. The biosynthesis of the title alkaloid as well as all total and formal syntheses of morphine and codeine published after 1996 are discussed in detail. The last section of this chapter provides a detailed overview of medicinally relevant derivatives of the title alkaloid.
Collapse
Affiliation(s)
- Christopher Wicks
- Department of Chemistry and Centre for Biotechnology, Brock University, St. Catharines, ON, Canada
| | - Tomas Hudlicky
- Department of Chemistry and Centre for Biotechnology, Brock University, St. Catharines, ON, Canada
| | - Uwe Rinner
- IMC Fachhochschule Krems/IMC University of Applied Sciences Krems, Krems, Austria.
| |
Collapse
|
3
|
Gutman ES, Bow E, Li F, Sulima A, Kaska S, Crowley R, Prisinzano TE, Lee YS, Hassan SA, Imler GH, Deschamps JR, Jacobson AE, Rice KC. G-Protein biased opioid agonists: 3-hydroxy- N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9. RSC Med Chem 2020; 11:896-904. [PMID: 33479684 DOI: 10.1039/d0md00104j] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 06/11/2020] [Indexed: 12/27/2022] Open
Abstract
A series of compounds have been synthesized with a variety of substituents based on a three-carbon chain at the C9-position of 3-hydroxy-N-phenethyl-5-phenylmorphan (3-(2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol). Three of these were found to be μ-opioid receptor agonists in the inhibition of forskolin-induced cAMP accumulation assay and they did not recruit β-arrestin at all in the PathHunter assay and in the Tango assay. Compound 12 (3-((1S,5R,9R)-2-phenethyl-9-propyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol), 13 (3-((1S,5R,9R)-9-((E)-3-hydroxyprop-1-en-1-yl)-2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol), and 15a (3-((1S,5R,9R)-9-(2-hydroxypropyl)-2-phenethyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol) were partial μ-agonists. Two of them had moderate efficacies (E MAX ca. 65%) and one had lower efficacy, and they were ca. 5, 3, and 4 times more potent, respectively, than morphine in vitro. Computer simulations were carried out to provide a molecular basis for the high bias ratios of the C9-substituted 5-phenylmorphans toward G-protein activation.
Collapse
Affiliation(s)
- Eugene S Gutman
- Drug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . ; ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200
| | - Eric Bow
- Drug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . ; ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200
| | - Fuying Li
- Drug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . ; ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200
| | - Agnieszka Sulima
- Drug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . ; ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200
| | - Sophia Kaska
- Department of Pharmaceutical Sciences , College of Pharmacy , University of Kentucky , 789 S. Limestone Street , Lexington , Kentucky 40536 , USA
| | - Rachel Crowley
- Department of Medicinal Chemistry , School of Pharmacy , University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott , Lawrence , Kansas 66045 , USA
| | - Thomas E Prisinzano
- Department of Pharmaceutical Sciences , College of Pharmacy , University of Kentucky , 789 S. Limestone Street , Lexington , Kentucky 40536 , USA.,Department of Medicinal Chemistry , School of Pharmacy , University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott , Lawrence , Kansas 66045 , USA
| | - Yong-Sok Lee
- Center for Molecular Modeling, Center for Information Technology , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-5624 , USA
| | - Sergio A Hassan
- Center for Molecular Modeling, Center for Information Technology , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-5624 , USA
| | - Gregory H Imler
- Center for Biomolecular Science and Engineering , Naval Research Laboratory , Washington DC , 20375-0001 , USA
| | - Jeffrey R Deschamps
- Center for Biomolecular Science and Engineering , Naval Research Laboratory , Washington DC , 20375-0001 , USA
| | - Arthur E Jacobson
- Drug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . ; ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200
| | - Kenner C Rice
- Drug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . ; ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200
| |
Collapse
|
4
|
Truver MT, Smith CR, Garibay N, Kopajtic TA, Swortwood MJ, Baumann MH. Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats. Neuropharmacology 2020; 177:108195. [PMID: 32533977 DOI: 10.1016/j.neuropharm.2020.108195] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 06/03/2020] [Accepted: 06/08/2020] [Indexed: 02/01/2023]
Abstract
Novel synthetic opioids are appearing in recreational drug markets worldwide as adulterants in heroin or ingredients in counterfeit analgesic medications. Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (U-47700) is an example of a non-fentanyl synthetic opioid linked to overdose deaths. Here, we examined the pharmacodynamics and pharmacokinetics of U-47700 in rats. Male Sprague-Dawley rats were fitted with intravenous (i.v.) catheters and subcutaneous (s.c.) temperature transponders under ketamine/xylazine anesthesia. One week later, rats received s.c. injections of U-47700 HCl (0.3, 1.0 or 3.0 mg/kg) or saline, and blood samples (0.3 mL) were withdrawn via i.v. catheters at 15, 30, 60, 120, 240, 480 min post-injection. Pharmacodynamic effects were assessed at each blood withdrawal, and plasma was assayed for U-47700 and its metabolites by liquid chromatography tandem mass spectrometry. U-47700 induced dose-related increases in hot plate latency (ED50 = 0.5 mg/kg) and catalepsy (ED50 = 1.7 mg/kg), while the 3.0 mg/kg dose also caused hypothermia. Plasma levels of U-47700 rose linearly as dose increased, with maximal concentration (Cmax) achieved by 15-38 min. Cmax values for N-desmethyl-U-47700 and N,N-didesmethyl-U-47700 were delayed but reached levels in the same range as the parent compound. Pharmacodynamic effects were correlated with plasma U-47700 and its N-desmethyl metabolite. Using radioligand binding assays, U-47700 displayed high affinity for μ-opioid receptors (Ki = 11.1 nM) whereas metabolites were more than 18-fold weaker. Our data reveal that U-47700 induces typical μ-opioid effects which are related to plasma concentrations of the parent compound. Given its high potency, U-47700 poses substantial risk to humans who are inadvertently exposed to the drug.
Collapse
Affiliation(s)
- Michael T Truver
- Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, TX, USA
| | - Christina R Smith
- Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, TX, USA
| | - Nancy Garibay
- Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
| | - Theresa A Kopajtic
- Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
| | - Madeleine J Swortwood
- Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, TX, USA.
| | - Michael H Baumann
- Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.
| |
Collapse
|
5
|
The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of "Tail Wags Dog" Experiments. Molecules 2020; 25:molecules25112640. [PMID: 32517185 PMCID: PMC7321161 DOI: 10.3390/molecules25112640] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 06/02/2020] [Accepted: 06/03/2020] [Indexed: 11/17/2022] Open
Abstract
(−)-N-Phenethyl analogs of optically pure N-norhydromorphone were synthesized and pharmacologically evaluated in several in vitro assays (opioid receptor binding, stimulation of [35S]GTPγS binding, forskolin-induced cAMP accumulation assay, and MOR-mediated β-arrestin recruitment assays). “Body” and “tail” interactions with opioid receptors (a subset of Portoghese’s message-address theory) were used for molecular modeling and simulations, where the “address” can be considered the “body” of the hydromorphone molecule and the “message” delivered by the substituent (tail) on the aromatic ring of the N-phenethyl moiety. One compound, N-p-chloro-phenethynorhydromorphone ((7aR,12bS)-3-(4-chlorophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one, 2i), was found to have nanomolar binding affinity at MOR and DOR. It was a potent partial agonist at MOR and a full potent agonist at DOR with a δ/μ potency ratio of 1.2 in the ([35S]GTPγS) assay. Bifunctional opioids that interact with MOR and DOR, the latter as agonists or antagonists, have been reported to have fewer side-effects than MOR agonists. The p-chlorophenethyl compound 2i was evaluated for its effect on respiration in both mice and squirrel monkeys. Compound 2i did not depress respiration (using normal air) in mice or squirrel monkeys. However, under conditions of hypercapnia (using air mixed with 5% CO2), respiration was depressed in squirrel monkeys.
Collapse
|
6
|
Abstract
This paper is the fortieth consecutive installment of the annual anthological review of research concerning the endogenous opioid system, summarizing articles published during 2017 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides and receptors as well as effects of opioid/opiate agonists and antagonists. The review is subdivided into the following specific topics: molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors (1), the roles of these opioid peptides and receptors in pain and analgesia in animals (2) and humans (3), opioid-sensitive and opioid-insensitive effects of nonopioid analgesics (4), opioid peptide and receptor involvement in tolerance and dependence (5), stress and social status (6), learning and memory (7), eating and drinking (8), drug abuse and alcohol (9), sexual activity and hormones, pregnancy, development and endocrinology (10), mental illness and mood (11), seizures and neurologic disorders (12), electrical-related activity and neurophysiology (13), general activity and locomotion (14), gastrointestinal, renal and hepatic functions (15), cardiovascular responses (16), respiration and thermoregulation (17), and immunological responses (18).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, CUNY, 65-30 Kissena Blvd., Flushing, NY, 11367, United States.
| |
Collapse
|
7
|
Prchalová E, Hin N, Thomas AG, Veeravalli V, Ng J, Alt J, Rais R, Rojas C, Li Z, Hihara H, Aoki M, Yoshizawa K, Nishioka T, Suzuki S, Kopajtic T, Chatrath S, Liu Q, Dong X, Slusher BS, Tsukamoto T. Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRGPRX1) Agonists. J Med Chem 2019; 62:8631-8641. [PMID: 31498617 PMCID: PMC10079166 DOI: 10.1021/acs.jmedchem.9b01003] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Mas-related G-protein-coupled receptor X1 (MRGPRX1) is a human sensory neuron-specific receptor and has been actively investigated as a therapeutic target for the treatment of pain. By use of two HTS screening hit compounds, 4-(4-(benzyloxy)-3-methoxybenzylamino)benzimidamide (5a) and 4-(2-(butylsulfonamido)-4-methylphenoxy)benzimidamide (11a), as molecular templates, a series of human MRGPRX1 agonists were synthesized and evaluated for their agonist activity using HEK293 cells stably transfected with human MrgprX1. Conversion of the benzamidine moiety into a 1-aminoisoquinoline moiety carried out in the later stage of structural optimization led to the discovery of a highly potent MRGPRX1 agonist, N-(2-(1-aminoisoquinolin-6-yloxy)-4-methylphenyl)-2-methoxybenzenesulfonamide (16), not only devoid of positively charged amidinium group but also with superior selectivity over opioid receptors. In mice, compound 16 displayed favorable distribution to the spinal cord, the presumed site of action for the MRGPRX1-mediated analgesic effects.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Hiroe Hihara
- Tsukuba Research Laboratories , Eisai Co., Ltd. , Tsukuba , Ibaraki 300-2635 , Japan
| | - Mika Aoki
- Tsukuba Research Laboratories , Eisai Co., Ltd. , Tsukuba , Ibaraki 300-2635 , Japan
| | - Kyoko Yoshizawa
- Tsukuba Research Laboratories , Eisai Co., Ltd. , Tsukuba , Ibaraki 300-2635 , Japan
| | - Tomoki Nishioka
- Tsukuba Research Laboratories , Eisai Co., Ltd. , Tsukuba , Ibaraki 300-2635 , Japan
| | - Shuichi Suzuki
- Tsukuba Research Laboratories , Eisai Co., Ltd. , Tsukuba , Ibaraki 300-2635 , Japan
| | - Theresa Kopajtic
- Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit , National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health , Baltimore , Maryland 21224 , United States
| | - Sheena Chatrath
- Department of Anesthesiology and Center for the Study of Itch , Washington University School of Medicine , St. Louis , Missouri 63110 , United States
| | - Qin Liu
- Department of Anesthesiology and Center for the Study of Itch , Washington University School of Medicine , St. Louis , Missouri 63110 , United States
| | | | | | | |
Collapse
|
8
|
Baumann MH, Kopajtic TA, Madras BK. Pharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis. Trends Pharmacol Sci 2019; 39:995-998. [PMID: 30454770 DOI: 10.1016/j.tips.2018.09.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 09/06/2018] [Accepted: 09/10/2018] [Indexed: 01/11/2023]
Abstract
The United States is experiencing an epidemic of opioid overdose deaths. Many of the recent fatalities are associated with illicitly manufactured fentanyl, which is being added to heroin and counterfeit pain pills. The crisis is further exacerbated by the emergence of an increasing number of novel synthetic opioids (NSOs), including various fentanyl analogs and non-fentanyl compounds that display potent agonist actions at the μ-opioid receptor. Importantly, most users are unaware of their exposure to fentanyl and NSOs. Stemming the tide of opioid-related fatalities will require a coordinated multidisciplinary response from policy makers, law enforcement personnel, first responders, treatment providers, family members, and scientists. To this end, basic research in pharmacology can contribute significantly to mitigating the crisis through efforts to characterize the biological effects of NSOs, discover more effective antidotes for overdose rescue, and develop safer medications for treating addiction and alleviating pain.
Collapse
Affiliation(s)
- Michael H Baumann
- Designer Drug Research Unit, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA.
| | - Theresa A Kopajtic
- Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA
| | - Bertha K Madras
- Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA
| |
Collapse
|
9
|
Zhu F, Aisa HA, Zhang J, Hu T, Sun C, He Y, Xie Y, Shen J. Development of a Robust Process for the Preparation of High-Quality 4-Methylenepiperidine Hydrochloride. Org Process Res Dev 2018. [DOI: 10.1021/acs.oprd.7b00350] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Fuqiang Zhu
- Key
Laboratory of Plant Resources and Chemistry in Arid Regions, Xinjiang
Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, South Beijing Road 40-1, Urumqi, Xinjiang 830011, P. R. China
- University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China
| | - Haji A. Aisa
- Key
Laboratory of Plant Resources and Chemistry in Arid Regions, Xinjiang
Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, South Beijing Road 40-1, Urumqi, Xinjiang 830011, P. R. China
| | - Jian Zhang
- Topharman Shanghai
Co., Ltd., Building 1, No. 388 Jialilue
Road, Zhangjiang Hitech Park, Shanghai 201209, P. R. China
| | - Tianwen Hu
- Topharman Shanghai
Co., Ltd., Building 1, No. 388 Jialilue
Road, Zhangjiang Hitech Park, Shanghai 201209, P. R. China
| | - Changliang Sun
- Topharman Shanghai
Co., Ltd., Building 1, No. 388 Jialilue
Road, Zhangjiang Hitech Park, Shanghai 201209, P. R. China
| | - Yang He
- CAS
Key Laboratory for Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China
| | - Yuanchao Xie
- CAS
Key Laboratory for Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China
| | - Jingshan Shen
- CAS
Key Laboratory for Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China
| |
Collapse
|